Reconstruction and Computational Modelling for Inherited Metabolic Diseases
Our overall objectives are to accelerate the diagnosis, and enable personalised management, of inherited metabolic diseases (IMDs). Established academic technology for statistical genomic analysis, deep learning-based prediction o...
ver más
31/05/2027
OLLSCOIL NA GAILLI...
8M€
Presupuesto del proyecto: 8M€
Líder del proyecto
UNIVERSITY OF GALWAY
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Fecha límite participación
Sin fecha límite de participación.
Financiación
concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto
el día 2023-06-01
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto Recon4IMD
Duración del proyecto: 47 meses
Fecha Inicio: 2023-06-01
Fecha Fin: 2027-05-31
Líder del proyecto
UNIVERSITY OF GALWAY
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
8M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Our overall objectives are to accelerate the diagnosis, and enable personalised management, of inherited metabolic diseases (IMDs). Established academic technology for statistical genomic analysis, deep learning-based prediction of protein structure, and whole-body metabolic network modelling shall be applied to generate personalised computational models, given patient-derived genomic, transcriptomic, proteomic and metabolomic data. To train diagnostic models, a comprehensive clinical team will recruit 1,945 diagnosed patients with a wide variety of IMDs, then validate the clinical utility of personalised computational models on a set of 685 undiagnosed patients. An enhanced human metabolic network reconstruction, especially for lipid metabolism, reaction kinetics and inherited metabolic disease pathways, will increase the predictive capacity of cellular and whole-body metabolic network models. As an exemplar for other IMDs, personalised computational modelling will be used to identify compensatory and aggravating mechanisms that associate with clinical severity in Gaucher disease. The predictive capacity of personalised models will be validated by comparison with additional empirical investigations of protein structure and function as well as metabolomics, tracer-based metabolomics and proteomics of patient-derived in vitro disease models. To maximise the potential for impact, personalised modelling software will be developed to be generally applicable to a broad variety of IMDs, and implemented in a way that is both accessible to clinicians and admissible to regulatory authorities. Sustainability will be promoted by development of a roadmap for a European foundation to aid personalised diagnosis and management of IMDs, informed by broad stakeholder consultation. This is a unique opportunity to realise the potential of personalised computational modelling for a broad set of rare diseases, which is a field where European collaboration is an essential for progress.